Nuclear Threat: Ukraine to Receive Israeli Placental Therapy for Radiation Damage.

The Ukrainian umbilical cord blood bank Hemafund has entered into an agreement with Pluri for the supply of a new drug PLX-R18 for the treatment of radiation sickness. This is an important step in ensuring protection against nuclear dangers, especially after recent threats and shelling of nuclear power plants.

According to the agreement, Pluri will produce 12,000 doses of the drug, enough to treat 6,000 patients, and Hemafund will be responsible for their delivery to medical facilities in Ukraine. Working with stem cells from the placenta, this drug restores all types of blood cells affected by radiation.

As part of the cooperation, clinical trials will be conducted and necessary permits obtained for the registration of the drug. In addition, Pluri has a large cell therapy manufacturing facility in Haifa that can be mobilized in case of emergencies.

The application of PLX-R18 could be a major breakthrough in the treatment of radiation exposure and provide protection in the event of nuclear accidents. Already approved by the FDA, this drug can assist in lifesaving efforts following radiation-related events.

The collaboration between Hemafund and Pluri is an important step in ensuring protection against nuclear threats and the distribution of a new drug for the treatment of radiation sickness. This drug, developed using stem cells, could save the lives of thousands of patients and become an effective means of combating radiation exposure.